Your browser doesn't support javascript.
loading
Exploring the anti-myeloma potential of composite nanoparticles As4S4/Fe3O4: Insights from in vitro, ex vivo and in vivo studies.
Cholujova, Danka; Bujnakova, Zdenka Lukacova; Dutkova, Erika; Valuskova, Zuzana; Csicsatkova, Nikoleta; Suroviakova, Katarina; Marinkovicova, Maria Elisabeth; Zbellova, Linda; Koklesova, Lenka; Sedlak, Jan; Hideshima, Teru; Anderson, Kenneth C; Jakubikova, Jana.
Afiliación
  • Cholujova D; Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
  • Bujnakova ZL; Institute of Geotechnics, Department of Mechanochemistry, Slovak Academy of Sciences, Watsonova 45, 04001 Kosice, Slovakia.
  • Dutkova E; Institute of Geotechnics, Department of Mechanochemistry, Slovak Academy of Sciences, Watsonova 45, 04001 Kosice, Slovakia.
  • Valuskova Z; Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
  • Csicsatkova N; Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
  • Suroviakova K; Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
  • Marinkovicova ME; Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
  • Zbellova L; Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
  • Koklesova L; Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia; Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 03601 Martin, Slovaki
  • Sedlak J; Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
  • Hideshima T; Dana Farber Cancer Institute, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Anderson KC; Dana Farber Cancer Institute, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Jakubikova J; Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, v. v. i., Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia; Centre for Advanced Materials Application, Slovak Academy of Sciences, Dubravska cesta 9, 84511 Bratislava, Slovakia. Electronic
Nanomedicine ; 62: 102777, 2024 Nov.
Article en En | MEDLINE | ID: mdl-39111377
ABSTRACT
Given the profound multiple myeloma (MM) heterogeneity in clonal proliferation of malignant plasma cells (PCs) and anti-MM therapeutic potential of nanotherapies, it is inevitable to develop treatment plan for patients with MM. Two composite nanoparticles (NPs), As4S4/Fe3O4 (41) and As4S4/Fe3O4 (11) demonstrated effective anti-MM activity in in vitro, ex vivo, and in vivo in xenograft mouse model. Composite NPs triggered activation of p-ERK1/2/p-JNK, and downregulation of c-Myc, p-PI3K, p-4E-BP1; G2/M cell cycle arrest with increase in cyclin B1, histones H2AX/H3, activation of p-ATR, p-Chk1/p-Chk2, p-H2AX/p-H3; and caspase- and mitochondria-dependent apoptosis induction. NPs attenuated the stem cell-like side population in MM cells, both alone and in the presence of stroma. For a higher clinical response rate, As4S4/Fe3O4 (41) observed synergism with dexamethasone and melphalan, while As4S4/Fe3O4 (11) showed synergistic effects in combination with bortezomib, lenalidomide and pomalidomide anti-MM agents, providing the framework for further clinical evaluation of composite NPs in MM.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Animals / Humans Idioma: En Revista: Nanomedicine Asunto de la revista: BIOTECNOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Eslovaquia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Animals / Humans Idioma: En Revista: Nanomedicine Asunto de la revista: BIOTECNOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Eslovaquia